AKEBIA THERAPEUTICS, INC. (AKBA)
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
📉 **NEGATIVE** • Low confidence analysis (49%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (21%) **Content type:** Clinical